- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00528489
Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX-B (Gag, Pol, Env) Given Alone, With IL-12 DNA, or With a Dose Escalation of IL-15 DNA, in Healthy, HIV-1-uninfected Adults Participants
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
A vaccine that is effective against multiple strains of HIV remains the best option for preventing the spread of HIV. Plasmid DNA vaccines are inexpensive and easy to construct. When DNA vaccines are administered in combination with cytokines, such as IL-12 or IL-15, the immune response to the vaccine is increased. The purpose of this study is to determine the safety and tolerability of the DNA plasmid vaccine, PENNVAX-B when administered alone, or with IL-12 or IL-15 DNA adjuvants. The most effective and safe dose of IL-15 will also be determined during this study.
This study will last approximately 12 months. Participants will be randomly assigned to one of four groups. Group 1 will receive an injection of PENNVAX-B combined with 0.8 mg IL-15 in each deltoid or placebo. Group 2 will receive an injection of PENNVAX-B alone or placebo. Group 3 will receive an injection of PENNVAX-B combined with IL-12 in each deltoid or placebo. Group 4 will receive PENNVAX-B combined with 2 mg IL-15 or placebo. Injections will occur at study entry, Months 1, 3, and 6. Additional study visits will occur on Days 14, 42, 98, 182, 273, and 364. At these visits a brief physical, blood collection, interview, and risk reduction counseling will occur. At some visits HIV testing, urine collection, and pregnancy tests will also occur.
As of 05/30/08, participants will be enrolled into Groups 3 and 4 at a limited pace to allow for additional safety reviews for the first few participants in these groups. Additionally, safety data will be reviewed for Groups 1 and 2 to determine whether the remainder of participants in Groups 2, 3, and 4 will be enrolled.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- Alabama Vaccine CRS
-
-
California
-
San Francisco, California, Estados Unidos
- San Francisco Vaccine and Prevention CRS
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos
- Brigham and Women's Hosp. CRS
-
-
New York
-
Bronx, New York, Estados Unidos, 10456
- NY Blood Ctr./Bronx CRS
-
New York, New York, Estados Unidos, 10003
- NY Blood Ctr./Union Square CRS
-
New York, New York, Estados Unidos, 10032
- HIV Prevention & Treatment CRS
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos
- 3535 Market Street CRS
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos
- Vanderbilt Vaccine CRS
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- HIV-1 and -2 uninfected
- Willing to receive HIV test results
- Good general health
- Certain laboratory values within normal range or with site physician approval
- Negative for Hepatitis B surface antigen
- Negative Hepatitis C test
- Willing to use acceptable methods of contraception
Exclusion Criteria:
- HIV vaccines or placebos in prior HIV trial. Participants who can provide documentation that they received a placebo in a prior HIV trial may be eligible.
- Immunosuppressive medications within 168 days prior to first study vaccination. Participants using corticosteroid nasal spray for allergies or topical corticosteroids for mild, uncomplicated dermatitis are not excluded.
- Blood products within 120 days prior to first study vaccination
- Receipt of immunoglobulin within 60 days prior to first vaccination
- Live attenuated vaccines within 30 days prior to first study vaccination
- Any vaccine that is not a live attenuated vaccine within 14 days prior to first study vaccination
- Investigational research agents within 60 days prior to first study vaccination
- Current anti-tuberculosis (TB) preventive therapy or treatment clinically significant medical condition, abnormal physical exam findings, abnormal laboratory results, or past medical history that may affect current health. More information about this criterion can be found in the protocol.
- Any medical, psychiatric, social, occupational, or other condition or responsibility that in the opinion of the investigator would interfere with the study. More information about this criterion can be found in the protocol.
- Allergy to amide-type local anesthetics
- Serious adverse reactions to vaccines
- Autoimmune disease or immunodeficiency
- Active syphilis infection. Participants who have been fully treated for syphilis over 6 months prior to study entry are not excluded.
- Asthma other than mild, well-controlled asthma. More information on this criterion can be found in the protocol.
- Type 1 or type 2 diabetes mellitus. Participants with histories of isolated gestational diabetes are not excluded.
- Thyroidectomy or thyroid disease requiring medication during the 12 months prior to study entry
- Accumulation of fluid in the blood vessels (angioedema) within 3 years prior to study entry if episodes are considered serious or have required medication in the 2 years prior to study entry
- Uncontrolled hypertension
- Body Mass Index of 40 or greater OR of 35 or greater if certain other criteria apply. More information about these criteria can be found in the protocol
- Bleeding disorder
- Cancer. Participants with surgically removed cancer that is unlikely to recur are not excluded.
- Seizure disorder
- Absence of the spleen
- Pregnancy or breastfeeding
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: 1
PENNVAX-B with 0.8 mg IL-15 administered in both deltoids at Months 0, 1, 3, and 6
|
DNA vaccine containing the HIV genes Gag, Pol, and Env
Cytokine injection
|
Experimental: 2
PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
|
DNA vaccine containing the HIV genes Gag, Pol, and Env
|
Experimental: 3
PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
|
DNA vaccine containing the HIV genes Gag, Pol, and Env
Cytokine injection
|
Experimental: 4
PENNVAX-B with 2 mg IL-15 injected into both deltoids at Months 0, 1, 3, and 6
|
DNA vaccine containing the HIV genes Gag, Pol, and Env
Cytokine injection
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Safety data including local and systemic reactogenicity sign and symptoms, laboratory measures of safety, and adverse and serious adverse events
Periodo de tiempo: Throughout study
|
Throughout study
|
Safety data from Groups 1 and 4
Periodo de tiempo: Throughout study
|
Throughout study
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
HIV-1 specific interferon gamma ELISpot and/or intracellular cytokine staining T cell response
Periodo de tiempo: 2 weeks after 3rd and 4th vaccinations
|
2 weeks after 3rd and 4th vaccinations
|
HIV-1 specific neutralizing and binding antibody assays
Periodo de tiempo: 2 weeks after 3rd and 4th vaccinations
|
2 weeks after 3rd and 4th vaccinations
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Silla de estudio: Scott Parker, MD, HVTN, FHCRC
Publicaciones y enlaces útiles
Publicaciones Generales
- Jin X, Morgan C, Yu X, DeRosa S, Tomaras GD, Montefiori DC, Kublin J, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network. Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. Vaccine. 2015 May 11;33(20):2347-53. doi: 10.1016/j.vaccine.2015.03.036. Epub 2015 Mar 25.
- Johnston MI, Fauci AS. An HIV vaccine--evolving concepts. N Engl J Med. 2007 May 17;356(20):2073-81. doi: 10.1056/NEJMra066267. No abstract available.
- Ogawa H, Ueno M, Uchibori H, Matsumoto I, Seno N. Direct carbohydrate analysis of glycoproteins electroblotted onto polyvinylidene difluoride membrane from sodium dodecyl sulfate-polyacrylamide gel. Anal Biochem. 1990 Nov 1;190(2):165-9. doi: 10.1016/0003-2697(90)90175-9.
- McBurney SP, Ross TM. Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines. Curr Pharm Des. 2007;13(19):1957-64. doi: 10.2174/138161207781039841.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Infecciones por VIH
Otros números de identificación del estudio
- HVTN 070
- 10490 (Otro identificador: CTEP)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Infecciones por VIH
-
Icahn School of Medicine at Mount SinaiIRRASReclutamientoHemorragia Intraventricular (HIV)Estados Unidos
-
Yale UniversityTerminadoPrecocidad | Recién nacidos de muy bajo peso al nacer | Hemorragia Intraventricular (HIV) | Sangrado en el cerebroEstados Unidos
-
China Medical University HospitalDesconocidoDisplasia broncopulmonar | Bebés extremadamente prematuros | TLP grave que las terapias convencionales han fallado | Sin anomalías congénitas graves | no Hiv Severa Ni FPV QuísticaTaiwán
Ensayos clínicos sobre PennVax B
-
Inovio PharmaceuticalsTerminadoInfecciones por VIH | Infección por VIH-1Estados Unidos
-
National Institute of Allergy and Infectious Diseases...TerminadoInfecciones por VIHEstados Unidos
-
University of PennsylvaniaDrexel UniversityTerminadoInfección por VIHEstados Unidos
-
Steven DeeksNational Institute of Allergy and Infectious Diseases (NIAID); University of... y otros colaboradoresTerminado
-
National Institute of Allergy and Infectious Diseases...Terminado
-
National Institute of Allergy and Infectious Diseases...Dynavax Technologies CorporationActivo, no reclutandoInfección por VIH | Hepatitis BEstados Unidos, Haití, Botsuana, Filipinas, Tailandia, Brasil, Kenia, Malaui, Sudáfrica, Uganda, Vietnam
-
BioNTech SETerminadoCOVID-19 | Infección por SARS-CoV2 | Enfermedad respiratoria aguda por SARS-CoV-2 | SARS (Enfermedad)Estados Unidos, Alemania, Pavo, Sudáfrica
-
ChemoCentryxMedpace, Inc.TerminadoGlomeruloesclerosis Focal Segmentaria | FSGS | GlomeruloesclerosisEstados Unidos, Francia, Italia, Australia, Reino Unido, Canadá, Nueva Zelanda, Polonia
-
Indiana UniversityAlcon ResearchTerminadoMiopía | HipermetropíaEstados Unidos
-
Wright State UniversityReclutamientoCáncer de pielEstados Unidos